By Hein Pijnnaken · Updated August 21, 2026
Microdosing refers to the practice of taking sub-perceptual doses of a psychedelic substance, typically 1/10 to 1/20 of a recreational dose, with the intention of supporting cognitive or emotional wellbeing without inducing psychoactive effects. One question that surfaces regularly among facilitators and coaches is whether repeated, long-term microdosing could affect heart valve health. This article lays out where that concern originated, what the current research shows, and how established microdosing protocols address it.
Where the Cardiac Concern Comes From
The Fen-Phen Precedent
The concern traces back to the 1990s, when the weight-loss drug combination fenfluramine-phentermine, known as Fen-Phen, was withdrawn from the market after being linked to valvular heart disease (VHD). Researchers later identified the serotonin 2B receptor (5-HT2B) as the likely mechanism: sustained, strong activation of this receptor on heart valve tissue can lead to fibrosis and thickening. Several other medications with high 5-HT2B binding affinity, including methysergide, pergolide, and cabergoline, have since been linked to the same effect.
David Nichols and the Original 2017 Hypothesis
The link to psychedelic microdosing was first raised in a 2017 blog post by David Nichols, president of the Heffter Research Institute and one of the field’s most established pharmacologists. Nichols pointed out that LSD, like fenfluramine, activates the 5-HT2B receptor, and suggested this deserved further study. He was careful to frame it as an open question rather than a proven risk, and explicitly called for rigorous studies to assess it.
The Case Against Cardiac Risk: Fadiman and Korb’s Response
In 2019, James Fadiman and Sophia Korb addressed the concern directly in an invited comment for the Journal of Psychopharmacology. They argued that “the worry about cardiac valvulopathy is excessive” relative to the overall safety profile of classic psychedelics. Their reasoning rested on two points: the doses used in Fen-Phen therapy vastly exceeded microdosing amounts, and the Fen-Phen valvulopathy cases were all symptomatic, whereas no such cases had been reported among the thousands of people who had microdosed, some for over a year at that point.
What the Current Research Shows
A Systematic Review of Cardiovascular Safety
A 2023 review in Pharmacological Reports by Agnieszka Wsół examined the cardiovascular safety of classic psychedelics in detail. The review confirmed that psilocybin and LSD bind to 5-HT2B receptors, and noted that psilocybin shows relatively higher affinity for this receptor than LSD does. At the same time, the author was explicit that evidence from actual microdosing regimens remains insufficient, and that data on people with pre-existing cardiovascular disease is still lacking. Microdosing-related valvular risk, in other words, remains a research gap rather than a demonstrated outcome.
Modeling the Risk for Chronic Microdosing
A 2024 paper by Antonin Rouaud, Abigail Calder, and Gregor Hasler in the Journal of Psychopharmacology was the first to model this risk specifically for microdosing regimens. The authors compared the structural and receptor-binding properties of LSD and psilocybin to known cardiotoxins, and concluded the theoretical concern is worth taking seriously for regimens lasting several months or longer without interruption. They recommended further controlled research and periodic cardiac monitoring for long-term users.
The First Experimental Test: LSD Microdosing in Mice
The most direct evidence to date comes from a 2025 study in ACS Pharmacology & Translational Science (Vol. 8, Issue 11, pp. 3923-3931). Researchers administered sub-hallucinogenic doses of LSD to mice for eight weeks and used echocardiography to check for the same changes seen with known cardiotoxins. Serotonin and d-fenfluramine, used as positive controls, produced measurable ventricular thickening and valve regurgitation. The LSD groups showed no significant cardiac changes at either dose, at any point in the study. This is the first experimental data specific to microdosing-range exposure, and it did not find the effect the 5-HT2B hypothesis predicts, though a single animal study cannot rule out longer-term or human-specific effects.
Why Protocol Structure Matters: The Role of Scheduled Breaks
Nearly every source in this discussion, including those most concerned about cardiac risk, converges on one variable: duration of continuous exposure. Dr. Kelan Thomas, PharmD, the researcher most associated with renewing this concern in 2022, has since pointed to protocol structure as the key mitigating factor. In a 2024 interview, he noted that following a regimen with built-in pauses is “a safer model than continuous dosing without breaks.”
This is precisely the structure the Fadiman protocol and the MDI Protocol are built around. Both call for scheduled days off between doses, and both prescribe a full rest period, of at least two to four weeks, between microdosing cycles. The Microdosing Institute has recommended this structure since its protocols were first developed, independent of the cardiac discussion. The available research on 5-HT2B-related valvulopathy consistently identifies sustained, uninterrupted exposure as the relevant risk factor, which means a protocol built around regular pauses is aligned with what researchers on both sides of this debate recommend. This is not the same as a proven safety guarantee, but it does mean facilitators following the Fadiman or MDI Protocol are already applying the precaution the literature points toward.
Contraindications and Screening for Facilitators
For most healthy adults following a structured protocol, the current evidence does not show a demonstrated cardiac risk from microdosing. For a broader overview of safety considerations beyond the heart, see our guide to microdosing contraindications and side effects. Facilitators should still apply extra caution in specific cases:
- Clients with a pre-existing heart condition or history of valvular disease should consult a cardiologist before starting, and consider baseline echocardiographic screening.
- Clients taking other medications with 5-HT2B agonist activity (certain migraine or Parkinson’s medications) warrant particular caution, since effects may compound.
- Extended microdosing beyond several months without a scheduled break falls outside what current protocols recommend and outside what the available safety data covers.
The legal status of LSD and psilocybin varies by jurisdiction; in most countries both remain controlled substances outside of approved research or facilitated contexts, which is a separate consideration facilitators should factor into client guidance.
FAQ
Does microdosing cause heart valve damage?
No human studies have documented valvular heart disease from microdosing. The concern is based on a shared receptor mechanism (5-HT2B) with unrelated drugs known to cause valve damage at much higher, continuous doses, and the first experimental test in animals at microdosing-range doses found no cardiac changes.
Why are LSD and psilocybin compared to Fen-Phen at all?
Both activate the 5-HT2B receptor, the same receptor implicated in Fen-Phen-related valve disease. The comparison is about shared mechanism, not shared dosing pattern or outcome; the doses and exposure patterns differ substantially.
Does taking breaks between microdosing cycles reduce cardiac risk?
Researchers on both sides of this discussion, including Dr. Kelan Thomas, identify sustained uninterrupted exposure as the key risk variable. Protocols built around scheduled pauses, such as the Fadiman and MDI Protocols, align with this precaution, though this has not been tested directly in controlled trials.
Reflective Closing
The cardiac safety question around microdosing is a useful example of how a legitimate scientific hypothesis moves through a field. What began as a cautious, speculative observation from David Nichols in 2017 has since been tested, debated, and partially addressed by newer research, without ever being confirmed in humans or, so far, in the first animal model built specifically to test it. For facilitators, the responsible position is neither dismissal nor alarm: it means understanding the mechanism, staying current as new data emerges, and continuing to build guidance around the protocol structures the evidence consistently points toward.
The information in this article is for educational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider before making changes to medication or mental health treatment. Research into psychedelics is ongoing; findings mentioned reflect the current state of the scientific literature as of the publication date.
